Sante Ventures

Solu Therapeutics is a precision medicine company developing therapeutics focused on eliminating disease-driving cells. Its platform combines selective small-molecule binders with proprietary antibodies to create bifunctional therapeutics, targeting inflammatory and autoimmune diseases.

Endovascular Engineering is a preclinical stage company dedicated to advancing innovative mechanical thrombectomy solutions for peripheral medical conditions. The firm specializes in the development of clot removal technologies specifically designed to address venous thromboembolism, which encompasses critical health issues such as pulmonary embolism and deep vein thrombosis. By focusing on these areas, Endovascular Engineering aims to equip healthcare professionals with efficient and effective tools to enhance patient outcomes in the management of these vascular conditions.

Endogenex develops a novel endoscopic procedure using pulsed electric fields to regenerate the duodenal mucosa, aiming to improve glycemic control in patients with Type 2 Diabetes.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Reprieve Cardiovascular, Inc. is a medical device company based in Milford, Massachusetts, established in 2018. The company specializes in developing innovative fluid management technologies aimed at treating congestive heart failure. Its flagship product, the Reprieve technology, offers a solution for clinicians to precisely control the fluid volume in patients suffering from acute decompensated heart failure (ADHF). This ability to manage fluid levels is essential for improving cardiac care and assisting in the decongestion process for these patients. Reprieve Cardiovascular operates as a subsidiary of CardioRenal Systems, Inc.

Solu Therapeutics is a precision medicine company developing therapeutics focused on eliminating disease-driving cells. Its platform combines selective small-molecule binders with proprietary antibodies to create bifunctional therapeutics, targeting inflammatory and autoimmune diseases.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Developer of a secure SaaS collaboration platform for creating secure data access to support impactful algorithm validation and development. The platform ensures data security through end-to-end encryption, uses primary data from the source, eliminates risks of data exfiltration and IP interrogation, and acts as a matchmaker between data stewards and algorithm developers.

Surgical Safety Technologies is a company focused on enhancing the safety and efficiency of healthcare through its AI-driven medical technology platform. The company provides hospitals with data-driven solutions that empower surgeons by offering an objective assessment of both technical and non-technical skills based on academically validated frameworks. Its platform generates descriptive, predictive, and prescriptive insights that support informed clinical and operational decision-making, ultimately aiming to improve surgical quality and patient safety.

Wave Life is a new kind of mental health platform that makes emotional wellbeing an achievable part of everyday life. The app's mental health coach and toolkit empower users to live each day with intention. Mental health coaching helps to build self-awareness, discover values, and cope with stress.

Founded in 2012, ABK Biomedical specializes in developing embolotherapeutic products for treating hypervascular tumors. Its primary focus is improving treatment options for patients through innovative microsphere technology.

Founded in 2021, Sensorium Therapeutics is a Boston-based company developing novel FDA-approved psychoactive medicines using its proprietary drug discovery platform. The platform employs artificial intelligence and computational methods to accelerate the identification of new drug candidates for treating brain and mental health conditions.

RapidPulse, Inc. is a privately held medical device company focused on creating minimally invasive vascular products specifically for the treatment of ischemic stroke. The company's flagship innovation is the RapidPulse™ Cyclic Aspiration System, which features an advanced aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse is a spinout from Syntheon LLC, a medical device incubator committed to developing groundbreaking products within the industry.

Endovascular Engineering is a preclinical stage company dedicated to advancing innovative mechanical thrombectomy solutions for peripheral medical conditions. The firm specializes in the development of clot removal technologies specifically designed to address venous thromboembolism, which encompasses critical health issues such as pulmonary embolism and deep vein thrombosis. By focusing on these areas, Endovascular Engineering aims to equip healthcare professionals with efficient and effective tools to enhance patient outcomes in the management of these vascular conditions.

Founded in 2016, Geneos Therapeutics specializes in developing personalized cancer immunotherapies targeting neoantigens. Its proprietary platform enables the creation of tailored treatments based on individual patients' tumor mutations.

Reimagine Care is a health‑care company that delivers technology‑enabled services to support community‑based oncology practices and health‑system oncology departments. The company supplies the personnel, processes, and a robust technology platform that enable scalable, patient‑centric, and lower‑cost cancer care across multiple sites, including home‑based treatment. Founded in 2020 and headquartered in Nashville, Tennessee, Reimagine Care partners with health‑care systems and independent oncology practices to promote value‑based care and improve access to high‑quality cancer treatment.

Access Optics designs and manufactures precision and micro-scale optical components and assemblies for medical devices and other demanding applications. The company combines manufacturing engineering, process development, optical fabrication and advanced coating technology to deliver optics for tiny cameras and endoscopic equipment, including hermetic seals that withstand extreme pressures, temperatures and humidity. Its offerings support original equipment manufacturers in endoscopy, dermatology, aerospace and chromatography, enabling improved surgical outcomes and reliable performance in challenging environments.

Cryosa is a medical technology company specializing in the development of innovative treatments for obstructive sleep apnea.

RapidPulse, Inc. is a privately held medical device company focused on creating minimally invasive vascular products specifically for the treatment of ischemic stroke. The company's flagship innovation is the RapidPulse™ Cyclic Aspiration System, which features an advanced aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse is a spinout from Syntheon LLC, a medical device incubator committed to developing groundbreaking products within the industry.

Founded in 2016, Geneos Therapeutics specializes in developing personalized cancer immunotherapies targeting neoantigens. Its proprietary platform enables the creation of tailored treatments based on individual patients' tumor mutations.

Iterion Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on developing innovative therapeutics for cancer treatment. Established in 2010, the company specializes in targeted cancer therapies, with its lead product, Tegavivint, serving as a potent and selective inhibitor of the Wnt/b-catenin signaling pathway. This pathway is known to play a critical role in various cancer-related processes, including cell proliferation and immune evasion. Tegavivint has demonstrated pre-clinical efficacy in several cancer models, such as desmoid tumors, acute myeloid leukemia, osteosarcoma, and various solid tumors. Iterion Therapeutics is actively enrolling patients in a Phase I clinical study of Tegavivint for desmoid tumors at multiple clinical centers across the United States and Canada.

Nirogy Therapeutics is a biotechnology company focused on developing innovative small molecules that target cellular transporters to address chronic diseases, including cancer, autoimmune disorders, and inflammation. The company employs a transporter target platform that integrates transporter biology, structural biology, and computational chemistry to analyze underlying biological mechanisms. This approach informs drug design and development while also guiding patient selection strategies for new therapies. Nirogy is advancing a specific class of small molecules aimed at disrupting metabolic and immune processes within the tumor microenvironment, with additional programs targeting various disease pathways in oncology and autoimmune diseases, ultimately seeking to meet significant unmet medical needs in healthcare.

KelaHealth develops clinical decision support software for surgical care. Its Surgical Intelligence Platform uses patient data to generate predictive insights about individual risk of complications, offers recommended interventions at key decision points, and tracks long-term outcomes to improve care quality. The platform helps standardize surgeon practice, support quality and regulatory compliance, and optimize clinical operations for physicians and hospital administrators, creating a learning ecosystem that continuously enhances surgical outcomes. The company was founded in 2016 and is based in San Francisco, California.

KelaHealth develops clinical decision support software for surgical care. Its Surgical Intelligence Platform uses patient data to generate predictive insights about individual risk of complications, offers recommended interventions at key decision points, and tracks long-term outcomes to improve care quality. The platform helps standardize surgeon practice, support quality and regulatory compliance, and optimize clinical operations for physicians and hospital administrators, creating a learning ecosystem that continuously enhances surgical outcomes. The company was founded in 2016 and is based in San Francisco, California.

Libra Therapeutics is a biotechnology company dedicated to developing novel disease-modifying therapeutics for neurodegenerative diseases. Its platform focuses on restoring cellular balance through small molecule drugs that attenuate the production of neurotoxic proteins, targeting conditions such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease.

Cryosa is a medical technology company specializing in the development of innovative treatments for obstructive sleep apnea.

Glyscend Therapeutics is a biotechnology company focused on developing innovative treatments for metabolic diseases, particularly type 2 diabetes. Founded in 2014 and based in Baltimore, Maryland, Glyscend has created a non-invasive oral therapy designed to replicate the metabolic benefits of bariatric surgery. Their approach involves an ingestible intestinal coating that targets the duodenum, inhibiting key neurohormonal pathways to effectively manage glucose levels. This method allows patients to avoid the risks and complications associated with surgical procedures while providing healthcare professionals with a practical tool to treat type 2 diabetes rather than merely managing it. Glyscend is committed to enhancing patient outcomes by offering effective solutions that minimize side effects typically associated with diabetes treatments, such as weight gain and hypoglycemia.

BioStable Science & Engineering, Inc. is a cardiovascular device company based in Austin, Texas, that specializes in developing valve repair technologies as alternatives to valve replacement for patients with aortic valve disease. The company offers a range of HAART aortic valve repair technologies, including the HAART 300 aortic annuloplasty device, designed to reduce annular dilatation and restore three-dimensional annular geometry, and the HAART 200 device tailored for bicuspid aortic valve repair. Additionally, BioStable's aortic root restoration system aims to enhance surgical outcomes for patients with aortic insufficiency or aortic root aneurysm. Founded in 2008, BioStable leverages its expertise in product development, regulatory affairs, and clinical validation to minimize time to market for its innovative medical devices, ultimately improving patient care in the cardiovascular field.

Remedy provides an on-demand urgent and primary care service focusing on innovative delivery of care. Remedy delivers medical care in the form of 24/7 telemedicine and nurse access, lab visits, and house calls, for individual patients and large employer clients, enabling patients to get quality doorstep treatment at an affordable price. Remedy was founded in 2015 and is based in Austin, Texas.

Founded in 2016, Geneos Therapeutics specializes in developing personalized cancer immunotherapies targeting neoantigens. Its proprietary platform enables the creation of tailored treatments based on individual patients' tumor mutations.

Endogenex develops a novel endoscopic procedure using pulsed electric fields to regenerate the duodenal mucosa, aiming to improve glycemic control in patients with Type 2 Diabetes.

Farapulse, Inc. is a medical technology company based in Menlo Park, California, that specializes in the development and commercialization of catheter-based tools aimed at treating atrial fibrillation. Founded in 2012 and formerly known as Iowa Approach, Inc., the company offers an innovative product called FARAWAVE, which features advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is designed for both endocardial and epicardial approaches to atrial fibrillation ablation. Farapulse's portfolio includes a variety of catheters, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, enabling physicians to effectively isolate pulmonary veins and enhance the safety, accessibility, and cost-effectiveness of atrial fibrillation treatments for patients.

Iterion Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on developing innovative therapeutics for cancer treatment. Established in 2010, the company specializes in targeted cancer therapies, with its lead product, Tegavivint, serving as a potent and selective inhibitor of the Wnt/b-catenin signaling pathway. This pathway is known to play a critical role in various cancer-related processes, including cell proliferation and immune evasion. Tegavivint has demonstrated pre-clinical efficacy in several cancer models, such as desmoid tumors, acute myeloid leukemia, osteosarcoma, and various solid tumors. Iterion Therapeutics is actively enrolling patients in a Phase I clinical study of Tegavivint for desmoid tumors at multiple clinical centers across the United States and Canada.

Cryosa is a medical technology company specializing in the development of innovative treatments for obstructive sleep apnea.

HNI Healthcare is a technology-driven physician practice management company specializing in delivering comprehensive facility-based physician programs. By combining its physicians' expertise with advanced processes and technologies, HNI Healthcare helps healthcare facilities enhance key quality metrics through a more integrated care model.

Claret Medical, Inc. is a cardiovascular medical device company based in Santa Rosa, California, focused on developing cerebral vascular protection systems for transcatheter aortic valve implantation and other endovascular procedures. The company's flagship product, the Claret Medical Sentinel Cerebral Protection System, is a percutaneously delivered embolic protection device designed to capture and remove debris dislodged during these procedures, thereby reducing the risk of stroke. Additionally, Claret Medical offers small 6 French catheters that are inserted through an artery into the patient's right arm, guiding the system to the heart and effectively safeguarding the brain from embolic material during interventional procedures. Incorporated in 2009, Claret Medical aims to enhance patient safety and outcomes by preventing the entry of thrombus and debris into the cerebral vascular system during various cardiovascular interventions.

Millipede Inc. is a medical device company based in Santa Rosa, California, focused on developing innovative percutaneous solutions for mitral and tricuspid valve repair. Incorporated in 2012, the company specializes in a catheter-based approach, creating a semi-rigid annuloplasty ring designed to address conditions such as mitral and tricuspid regurgitation. This technology aims to replicate the gold standard in valve repair by reducing the valve annulus diameter, thereby restoring leaflet coaptation and alleviating severe mitral regurgitation. As of January 2019, Millipede operates as a subsidiary of Boston Scientific Corporation, enhancing its capacity to deliver effective treatment options for patients and healthcare providers worldwide.

EndoStim is a medical device company specializing in neurostimulation solutions for treating gastro-esophageal reflux disease (GERD). Its flagship product, a microstimulator, targets the lower esophageal sphincter muscle to restore normal function and provide long-term reflux control. EndoStim distributes its products globally and is headquartered in Dallas, Texas.

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, focused on developing and commercializing therapeutics for severe, rare, and genetic diseases. The company's lead product, LUM-201, is an oral small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. In addition to its primary focus, Lumos has a licensing agreement with Ellipses Pharma Limited for the development and commercialization of nanoparticle formulations aimed at oncology indications. Founded in 2011, Lumos Pharma also has a commitment to addressing Creatine Transporter Deficiency, leveraging exclusive licenses for technologies developed at the University of Cincinnati and collaborating with key opinion leaders and the National Institutes of Health. The company engages in both clinical and preclinical research, exploring treatments that may enhance immune responses against cancer, and has partnerships for manufacturing its therapeutics.

Farapulse, Inc. is a medical technology company based in Menlo Park, California, that specializes in the development and commercialization of catheter-based tools aimed at treating atrial fibrillation. Founded in 2012 and formerly known as Iowa Approach, Inc., the company offers an innovative product called FARAWAVE, which features advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is designed for both endocardial and epicardial approaches to atrial fibrillation ablation. Farapulse's portfolio includes a variety of catheters, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, enabling physicians to effectively isolate pulmonary veins and enhance the safety, accessibility, and cost-effectiveness of atrial fibrillation treatments for patients.

Farapulse, Inc. is a medical technology company based in Menlo Park, California, that specializes in the development and commercialization of catheter-based tools aimed at treating atrial fibrillation. Founded in 2012 and formerly known as Iowa Approach, Inc., the company offers an innovative product called FARAWAVE, which features advanced tissue-selective pulsed field ablation (PFA) therapy. This therapy is designed for both endocardial and epicardial approaches to atrial fibrillation ablation. Farapulse's portfolio includes a variety of catheters, such as over-the-wire, deflectable, linear, and circumferential lesion catheters, enabling physicians to effectively isolate pulmonary veins and enhance the safety, accessibility, and cost-effectiveness of atrial fibrillation treatments for patients.

HNI Healthcare is a technology-driven physician practice management company specializing in delivering comprehensive facility-based physician programs. By combining its physicians' expertise with advanced processes and technologies, HNI Healthcare helps healthcare facilities enhance key quality metrics through a more integrated care model.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and headquartered in Goleta, California. The company specializes in developing non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is a device that is inserted into the stomach through the mouth using a straightforward endoscopic procedure. This device is designed to enhance the sensation of fullness by causing the stomach to fill up faster and remain full longer, while also delaying gastric emptying. Through its innovative approach, BAROnova seeks to provide patients with effective tools for weight management without the need for surgery.

Founded in 2009, TVA Medical develops and manufactures catheter-based equipment for treating end-stage renal disease and peripheral vascular diseases. Its flagship product is the everlinQ endoAVF system, which creates an arterio-venous fistula using a minimally invasive, endovascular approach.

Terapio Corporation is a biopharmaceutical company based in Austin, Texas, founded in 2005. The company specializes in developing a pipeline of therapeutics that leverage the transport protein RLIP76, which plays a critical role in moving free-radical toxins out of cells to prevent significant damage. By enhancing the availability of this protein in normal cells, Terapio aims to improve their capacity to manage toxins from various sources, including chemicals and radiation. The therapeutics developed by Terapio serve as medical countermeasures against radiation exposure and chemical threats, targeting civilian, military, and first responder populations to provide both prophylactic and post-exposure treatment options.

Iterion Therapeutics, Inc. is a clinical-stage biotechnology company based in Houston, Texas, focused on developing innovative therapeutics for cancer treatment. Established in 2010, the company specializes in targeted cancer therapies, with its lead product, Tegavivint, serving as a potent and selective inhibitor of the Wnt/b-catenin signaling pathway. This pathway is known to play a critical role in various cancer-related processes, including cell proliferation and immune evasion. Tegavivint has demonstrated pre-clinical efficacy in several cancer models, such as desmoid tumors, acute myeloid leukemia, osteosarcoma, and various solid tumors. Iterion Therapeutics is actively enrolling patients in a Phase I clinical study of Tegavivint for desmoid tumors at multiple clinical centers across the United States and Canada.

Mirna Therapeutics, Inc. is a discovery-stage biopharmaceutical company that specializes in developing miRNA-directed therapies for human oncology. With a strong focus on research and a deep understanding of microRNA and cancer biology, Mirna is positioned to advance the emerging field of miRNA-based therapeutics. The company boasts a robust intellectual property portfolio that supports its innovative approach to cancer treatment.

BioStable Science & Engineering, Inc. is a cardiovascular device company based in Austin, Texas, that specializes in developing valve repair technologies as alternatives to valve replacement for patients with aortic valve disease. The company offers a range of HAART aortic valve repair technologies, including the HAART 300 aortic annuloplasty device, designed to reduce annular dilatation and restore three-dimensional annular geometry, and the HAART 200 device tailored for bicuspid aortic valve repair. Additionally, BioStable's aortic root restoration system aims to enhance surgical outcomes for patients with aortic insufficiency or aortic root aneurysm. Founded in 2008, BioStable leverages its expertise in product development, regulatory affairs, and clinical validation to minimize time to market for its innovative medical devices, ultimately improving patient care in the cardiovascular field.

Lyric Pharmaceuticals Inc. is a clinical-stage pharmaceutical company based in South San Francisco, California, focused on developing innovative therapeutics for critically ill and hospitalized patients. Founded in 2013, the company specializes in gastrointestinal therapeutics, addressing unmet medical needs within the hospital environment. Its primary product, ulimorelin, acts as a macrocyclic agonist of the hormone ghrelin and is being developed as LP101 to treat enteral feeding intolerance and other disorders affecting patients in intensive care units. Through its research and development efforts, Lyric Pharmaceuticals aims to improve patient care and outcomes in critical care settings.

Laguna Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and marketing of small molecule pharmaceuticals, specifically targeting the treatment of atrial fibrillation (AF) and atrial flutter (AFL). The company, originally established as ChanRx Corp. in 2006, rebranded to its current name in February 2015. With its headquarters in La Jolla, California, Laguna Pharmaceuticals is dedicated to advancing therapeutic options for patients suffering from these common cardiac conditions, which can lead to serious health complications such as heart attacks and strokes.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Claret Medical, Inc. is a cardiovascular medical device company based in Santa Rosa, California, focused on developing cerebral vascular protection systems for transcatheter aortic valve implantation and other endovascular procedures. The company's flagship product, the Claret Medical Sentinel Cerebral Protection System, is a percutaneously delivered embolic protection device designed to capture and remove debris dislodged during these procedures, thereby reducing the risk of stroke. Additionally, Claret Medical offers small 6 French catheters that are inserted through an artery into the patient's right arm, guiding the system to the heart and effectively safeguarding the brain from embolic material during interventional procedures. Incorporated in 2009, Claret Medical aims to enhance patient safety and outcomes by preventing the entry of thrombus and debris into the cerebral vascular system during various cardiovascular interventions.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Renascent Foundation offers evidence-based, trauma-informed care that addresses drug and alcohol addiction and concurrent mental health issues. They offer specialized addiction support programs for individuals, families, children, workplaces, organizations, and communities impacted by drug and alcohol addictions.

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, focused on developing and commercializing therapeutics for severe, rare, and genetic diseases. The company's lead product, LUM-201, is an oral small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. In addition to its primary focus, Lumos has a licensing agreement with Ellipses Pharma Limited for the development and commercialization of nanoparticle formulations aimed at oncology indications. Founded in 2011, Lumos Pharma also has a commitment to addressing Creatine Transporter Deficiency, leveraging exclusive licenses for technologies developed at the University of Cincinnati and collaborating with key opinion leaders and the National Institutes of Health. The company engages in both clinical and preclinical research, exploring treatments that may enhance immune responses against cancer, and has partnerships for manufacturing its therapeutics.

HNI Healthcare is a technology-driven physician practice management company specializing in delivering comprehensive facility-based physician programs. By combining its physicians' expertise with advanced processes and technologies, HNI Healthcare helps healthcare facilities enhance key quality metrics through a more integrated care model.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Ketra is a leading developer of advanced LED lighting solutions designed for high-end residential and commercial environments. The company specializes in creating high-performance, accurate lighting systems that integrate seamlessly with universally compatible controls, all from a single manufacturer. This cohesive approach not only simplifies the installation process but also enhances user experience through innovative technologies and user-friendly products. Ketra’s full-stack light-emitting diode components include an integrated control system that manages power and ensures color stability and uniform intensity. By focusing on creating natural light environments, Ketra aims to improve users' sleep, productivity, and overall wellness, contributing to healthier and more fulfilling lives.

Guided Interventions is a Cleveland-based medical device startup led by CEO Dr. Matthew Pollman. The company specializes in the development of innovative wire-based medical devices, particularly a fractional flow reserve (FFR) guidewire aimed at enhancing coronary catheterization procedures. This guidewire is engineered to improve maneuverability and handling, allowing healthcare professionals to obtain accurate FFR measurements effectively. By focusing on maximizing efficacy while minimizing risks and costs, Guided Interventions seeks to reduce the reliance on stents for opening blocked arteries and to alleviate the painful and potentially dangerous side effects associated with heart surgery. Ultimately, the company aims to empower doctors to better assess the physiological impact of coronary artery blockages, thereby improving patient outcomes.

Rise Health, Inc. is a healthcare services company based in Chicago, Illinois, that specializes in providing primary care solutions to physician practices and healthcare organizations across the United States. The company focuses on enhancing patient access to primary care and improving the care experience by enabling patients to engage effectively with their primary care providers. Rise Health equips physicians with essential tools and support to manage their patients' health more efficiently, optimizing the use of their time and skills. Additionally, the company assists clients in developing the necessary infrastructure to participate in accountable care organizations and adhere to the principles of patient-centered medical homes. Founded in 2009, Rise Health was previously known as Optizend, Inc.

Founded in 2009, TVA Medical develops and manufactures catheter-based equipment for treating end-stage renal disease and peripheral vascular diseases. Its flagship product is the everlinQ endoAVF system, which creates an arterio-venous fistula using a minimally invasive, endovascular approach.

Founded in 2010 by Michael Wilson, Healthcare Highways operates as an accountable care organization offering customized health plans. It partners with hospitals, providers, employers, payers, and brokers to deliver solutions such as TPA administration, stop-loss coverage, disease management, pharmacy benefit management services, and population health. The company's mission is to lower healthcare costs for members, providers, and employers by designing proactive solutions that anticipate industry challenges.

EndoStim is a medical device company specializing in neurostimulation solutions for treating gastro-esophageal reflux disease (GERD). Its flagship product, a microstimulator, targets the lower esophageal sphincter muscle to restore normal function and provide long-term reflux control. EndoStim distributes its products globally and is headquartered in Dallas, Texas.

Spinal Restoration, Inc. is a company focused on developing innovative, minimally invasive therapies for chronic low back pain. Established in 2004 and headquartered in New York, it specializes in the Biostat System, a proprietary resorbable biologic compound and delivery system aimed at treating chronic discogenic pain caused by internal disc disruptions. The Biostat System comprises BIOSTAT BIOLOGX Fibrin Sealant, a resorbable biologic tissue sealant, and a proprietary delivery device designed to administer the biologic directly to the intervertebral disc. This targeted approach addresses a significant patient population, as chronic disc pain affects approximately four million adults annually.

BAROnova, Inc. is a clinical-stage medical-device company founded in 2006 and headquartered in Goleta, California. The company specializes in developing non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is a device that is inserted into the stomach through the mouth using a straightforward endoscopic procedure. This device is designed to enhance the sensation of fullness by causing the stomach to fill up faster and remain full longer, while also delaying gastric emptying. Through its innovative approach, BAROnova seeks to provide patients with effective tools for weight management without the need for surgery.

EndoStim is a medical device company specializing in neurostimulation solutions for treating gastro-esophageal reflux disease (GERD). Its flagship product, a microstimulator, targets the lower esophageal sphincter muscle to restore normal function and provide long-term reflux control. EndoStim distributes its products globally and is headquartered in Dallas, Texas.

Spinal Restoration, Inc. is a company focused on developing innovative, minimally invasive therapies for chronic low back pain. Established in 2004 and headquartered in New York, it specializes in the Biostat System, a proprietary resorbable biologic compound and delivery system aimed at treating chronic discogenic pain caused by internal disc disruptions. The Biostat System comprises BIOSTAT BIOLOGX Fibrin Sealant, a resorbable biologic tissue sealant, and a proprietary delivery device designed to administer the biologic directly to the intervertebral disc. This targeted approach addresses a significant patient population, as chronic disc pain affects approximately four million adults annually.

Rex Bionics specializes in developing robotic medical devices for rehabilitation. Its flagship product is REX, a hands-free robotic device designed to assist individuals with mobility impairments in exercising, walking, and standing. Established in 2007, the company operates out of Auckland, New Zealand.

AbVitro is a biotechnology company based in Boston, Massachusetts, dedicated to advancing the treatment of complex diseases that involve the immune system. The company employs high-throughput genomic sequencing technology to analyze millions of tumor and blood cells, aiming to identify new therapeutic targets and biomarkers. By uncovering these targets, AbVitro simultaneously discovers and evaluates fully human antibody binders and T-cell receptors (TCRs) for their potential in immunotherapy. Their focus is on addressing unmet medical needs in the treatment of poorly understood human diseases, leveraging the capabilities of the human immune system to develop innovative therapeutic solutions.

LumaTherm, Inc.

EndoStim is a medical device company specializing in neurostimulation solutions for treating gastro-esophageal reflux disease (GERD). Its flagship product, a microstimulator, targets the lower esophageal sphincter muscle to restore normal function and provide long-term reflux control. EndoStim distributes its products globally and is headquartered in Dallas, Texas.

Laguna Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and marketing of small molecule pharmaceuticals, specifically targeting the treatment of atrial fibrillation (AF) and atrial flutter (AFL). The company, originally established as ChanRx Corp. in 2006, rebranded to its current name in February 2015. With its headquarters in La Jolla, California, Laguna Pharmaceuticals is dedicated to advancing therapeutic options for patients suffering from these common cardiac conditions, which can lead to serious health complications such as heart attacks and strokes.

HNI Healthcare is a technology-driven physician practice management company specializing in delivering comprehensive facility-based physician programs. By combining its physicians' expertise with advanced processes and technologies, HNI Healthcare helps healthcare facilities enhance key quality metrics through a more integrated care model.

Millipede Inc. is a medical device company based in Santa Rosa, California, focused on developing innovative percutaneous solutions for mitral and tricuspid valve repair. Incorporated in 2012, the company specializes in a catheter-based approach, creating a semi-rigid annuloplasty ring designed to address conditions such as mitral and tricuspid regurgitation. This technology aims to replicate the gold standard in valve repair by reducing the valve annulus diameter, thereby restoring leaflet coaptation and alleviating severe mitral regurgitation. As of January 2019, Millipede operates as a subsidiary of Boston Scientific Corporation, enhancing its capacity to deliver effective treatment options for patients and healthcare providers worldwide.

Explorys, Inc. is a healthcare cloud-computing company based in Cleveland, Ohio, founded in 2009. It specializes in providing a comprehensive platform for enterprise performance management tailored to integrated healthcare systems across the United States. The platform facilitates data management, business intelligence, and population analytics, allowing healthcare organizations to identify patterns in diseases, treatments, and outcomes. By enabling the collection and integration of diverse data types—including clinical, claims, billing, and patient information—Explorys supports healthcare providers, payers, and life sciences organizations in improving care quality and operational efficiency. Additionally, the platform aids in enhancing research capabilities and accelerating product development within the healthcare sector. As of 2015, Explorys operates as a subsidiary of International Business Machines Corporation.

Explorys, Inc. is a healthcare cloud-computing company based in Cleveland, Ohio, founded in 2009. It specializes in providing a comprehensive platform for enterprise performance management tailored to integrated healthcare systems across the United States. The platform facilitates data management, business intelligence, and population analytics, allowing healthcare organizations to identify patterns in diseases, treatments, and outcomes. By enabling the collection and integration of diverse data types—including clinical, claims, billing, and patient information—Explorys supports healthcare providers, payers, and life sciences organizations in improving care quality and operational efficiency. Additionally, the platform aids in enhancing research capabilities and accelerating product development within the healthcare sector. As of 2015, Explorys operates as a subsidiary of International Business Machines Corporation.

EndoStim is a medical device company specializing in neurostimulation solutions for treating gastro-esophageal reflux disease (GERD). Its flagship product, a microstimulator, targets the lower esophageal sphincter muscle to restore normal function and provide long-term reflux control. EndoStim distributes its products globally and is headquartered in Dallas, Texas.

Founded in 2009, TVA Medical develops and manufactures catheter-based equipment for treating end-stage renal disease and peripheral vascular diseases. Its flagship product is the everlinQ endoAVF system, which creates an arterio-venous fistula using a minimally invasive, endovascular approach.

Terapio Corporation is a biopharmaceutical company based in Austin, Texas, founded in 2005. The company specializes in developing a pipeline of therapeutics that leverage the transport protein RLIP76, which plays a critical role in moving free-radical toxins out of cells to prevent significant damage. By enhancing the availability of this protein in normal cells, Terapio aims to improve their capacity to manage toxins from various sources, including chemicals and radiation. The therapeutics developed by Terapio serve as medical countermeasures against radiation exposure and chemical threats, targeting civilian, military, and first responder populations to provide both prophylactic and post-exposure treatment options.

Zeno Corporation is the maker of health and beauty products. They specifically focus on thermal-based, over-the-counter products for skin. Their primary product is called Zeno HOT SPOT and is centered around patented technology ClearPointâ„¢

HNI Healthcare is a technology-driven physician practice management company specializing in delivering comprehensive facility-based physician programs. By combining its physicians' expertise with advanced processes and technologies, HNI Healthcare helps healthcare facilities enhance key quality metrics through a more integrated care model.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Rise Health, Inc. is a healthcare services company based in Chicago, Illinois, that specializes in providing primary care solutions to physician practices and healthcare organizations across the United States. The company focuses on enhancing patient access to primary care and improving the care experience by enabling patients to engage effectively with their primary care providers. Rise Health equips physicians with essential tools and support to manage their patients' health more efficiently, optimizing the use of their time and skills. Additionally, the company assists clients in developing the necessary infrastructure to participate in accountable care organizations and adhere to the principles of patient-centered medical homes. Founded in 2009, Rise Health was previously known as Optizend, Inc.

BioStable Science & Engineering, Inc. is a cardiovascular device company based in Austin, Texas, that specializes in developing valve repair technologies as alternatives to valve replacement for patients with aortic valve disease. The company offers a range of HAART aortic valve repair technologies, including the HAART 300 aortic annuloplasty device, designed to reduce annular dilatation and restore three-dimensional annular geometry, and the HAART 200 device tailored for bicuspid aortic valve repair. Additionally, BioStable's aortic root restoration system aims to enhance surgical outcomes for patients with aortic insufficiency or aortic root aneurysm. Founded in 2008, BioStable leverages its expertise in product development, regulatory affairs, and clinical validation to minimize time to market for its innovative medical devices, ultimately improving patient care in the cardiovascular field.

Zeno Corporation is the maker of health and beauty products. They specifically focus on thermal-based, over-the-counter products for skin. Their primary product is called Zeno HOT SPOT and is centered around patented technology ClearPointâ„¢

Protein Discovery is a life sciences company based in Knoxville, Tennessee, focused on developing and commercializing sample preparation technologies for protein and peptide analysis using mass spectrometry. The company offers several key products: the Gelfree 8100 fractionation system, which separates complex protein mixtures into liquid-phase molecular weight fractions; the Passport 1200 sample preparation system, designed to enrich low molecular weight proteins and peptides while removing matrix interferences for high-throughput quantification applications; and PPS Silent Surfactant, a reagent that solubilizes membrane proteins and cleaves to eliminate detergent interference. Additionally, Protein Discovery provides the UPX universal protein extraction kit for detergent extraction of proteins from cells and tissues. These products are marketed through Agilent Technologies and online, serving life science researchers and drug development scientists both domestically and internationally. Founded in 2001 as Qgenics Biosciences, Inc., the company rebranded to Protein Discovery, Inc. in April 2004.

Spinal Restoration, Inc. is a company focused on developing innovative, minimally invasive therapies for chronic low back pain. Established in 2004 and headquartered in New York, it specializes in the Biostat System, a proprietary resorbable biologic compound and delivery system aimed at treating chronic discogenic pain caused by internal disc disruptions. The Biostat System comprises BIOSTAT BIOLOGX Fibrin Sealant, a resorbable biologic tissue sealant, and a proprietary delivery device designed to administer the biologic directly to the intervertebral disc. This targeted approach addresses a significant patient population, as chronic disc pain affects approximately four million adults annually.